Manufacturing

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Brian Feth, Xcell Biosciences; Thomas Heathman, Ori Biotech; and Matthew Lauber, Waters Corporation go behind the headlines and discuss commercialization challenges in the cell and gene therapy space; advances in new genomics tools from Roche, Illumina, and Eikon; and the latest development and manufacturing partnerships. 

Behind the Headlines Episode 12–Cell and Gene Therapies, New Genomics Tools, and Recent Partnerships

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new Medicare drug price negotiations, and more. 

Behind the Headlines: Sana’s Type 1 Diabetes Breakthrough, Drug Price Negotiations, and More

Feliza Mirasol is the science editor for 

Articles

The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days. 

Trenchant BioSystems Partners with Autolomous to Form Integrated Automated CGT Manufacturing Platform

Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.

Cytiva Collaborates with Cellular Origins to Deliver Automated Manufacturing for CGTs

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Although specifics about the milestone were not immediately provided, Scribe is eligible to receive more than $1.2 billion for certain research, development, regulatory, and commercial benchmarks.

Scribe Reports Milestone for In Vivo Program Collaboration with Sanofi

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.

Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates

Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies. 

Behind the Headlines: Pandemic Preparedness, Novel mRNA Applications, and More

Nicholas Saraceno is editor at Pharmaceutical Commerce.

The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.

Fujifilm's Cell Therapy Facility Expansion Completed

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's  IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

TrakCel’s OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.

Manufacturing, Cell Therapies